Pisapia A, Bine-Scheck F, Schenowitz A, Domerego J J, Maraud L, Canler A, Labban N, Viart R, Aubry P, Beruben E
Service de Cardiologie, Hôpital Saint-Joseph, Marseille.
Ann Cardiol Angeiol (Paris). 1994 Mar;43(3):143-51.
Cibenzoline is a Vaughan-Williams class I anti-arrhythmic with properties intermediate between subclasses IA and IC which limit the incidence of proarrhythmic effects. These specific properties of the drug facilitate the prescription of cibenzoline in cardiology, particularly for the prevention of recurrent atrial arrhythmia: fibrillation, flutter, atrial tachycardia. This study demonstrates that cibenzoline is effective in these indications, since only 23% of the patients had relapsed after 6 months. This efficacy, combined with the good tolerance of the treatment, makes it possible to recommend the prescription of cibenzoline as a first-line treatment for the prevention of atrial arrhythmia. It represents an effective and safe option.
西苯唑啉是一种 Vaughan-Williams 分类 I 类抗心律失常药物,其特性介于 IA 和 IC 亚类之间,可降低促心律失常效应的发生率。该药物的这些特殊性质有助于其在心脏病学中的处方应用,特别是用于预防复发性房性心律失常:房颤、房扑、房性心动过速。本研究表明,西苯唑啉在这些适应症中有效,因为 6 个月后只有 23% 的患者复发。这种疗效与良好的治疗耐受性相结合,使得推荐将西苯唑啉作为预防房性心律失常的一线治疗药物成为可能。它是一种有效且安全的选择。